Original Article

Evaluation of the Outcome of Antiviral Therapy among Individ-uals Infected HIV-1 in Suqian District of Jiangsu Province, China


Background: To evaluate the condition of antiviral therapy (ART) for individuals infected HIV-1 in Suqian district of Jiangsu Province, China.

Methods: Altogether, 561 HIV-positive patients who received antiviral therapy in Suqian district in 2019 were recruited. EDTA anticoagulated blood was collected and separated to obtain the plasma samples. Viral load (VL) were tested for evaluating the outcome of ART. Then samples with VL beyond 1000IU/mL were used to conduct the molecular test in order to master the characters of HIV-1 and the prevalence of resistance strains.

Results: VL results showed that the virus in 91.1% of the patients who received continuous antiviral treatment for more than 6 months were effectively inhibited (VL ≤ 1000 IU / ml). Among the 50 patients who failed in the treatment, 46 HIV-1 pol gene sequences were obtained, and the positive rate was 92.0%. The most prevalent strain was CRF_ 07bc (32.6%), and new epidemic strains, such as 67_01B、79_0107、87_cpx, were popular in this district. Drug resistance test results showed that 56.5% of the patients failed in antiviral treatment due to drug resistance, mainly resistant to the national first-line antiviral drug 3TC. Drug-resistant strains were not found in 43.5% of the patients.

Conclusion: ART achieved a satisfied result in Suqian district, but the main cause resulting in ART-failure was resistant, so it is very necessary to enhance the education of adherence prior to the initiation of ART.

1. Kiertiburanakul S, Boettiger D, Lee MP, et al (2014). Trends of CD4 cell count levels at the initiation of antiretroviral therapy over time and factors associated with late initiation of antiretroviral therapy among Asian HIV-positive patients. J Int AIDS Soc, 17(1):18804.
2. Liang S, Shen Z, Yan J, et al (2015). Low Virologic Failure and Drug Resistance among HIV-Infected Patients Receiving Hospital-Based ART While Care and Outreach through Community in Guangxi, China. Front Public Health, 3:244.
3. Hao Y, Cui Y, Sun XH, et al (2014). A retrospective study of HIV/AIDS situation: a ten-year implementation of "four frees and one care" policy in China. Chinese Journal of Disease Control & Prevention, 18(05): 369-374.
4. Li H, Chang S, Han Y, Zhuang D, et al (2016). The prevalence of drug resistance among treatment-naïve HIV-1-infected individuals in China during pre- and post- 2004 . BMC Infect Dis, 16(1): 605.
5. Dong K, Ye L, Leng Y, et al (2019). Prevalence of HIV-1 Drug Resistance among Patients with Antiretroviral Therapy Failure in Sichuan, China, 2010-2016. Tohoku J Exp Med, 247(1): 1-12.
6. Zhao S, Feng Y, Hu J, et al (2018). Prevalence of Transmitted HIV drug resistance in antiretroviral treatment naïve newly diagnosed individuals in China. Sci Rep, 8(1): 12273.
7. Xu Y, Peng X, Peng X, et al (2018). Characterization of HIV-1 subtypes and transmitted drug resistance among treatment-naive HIV-infected individuals in Zhejiang, China, 2014-2017. Arch Virol, 163(8): 2233-2237.
8. Williams AB (1999). Adherence to highly active antiretroviral therapy. Nurs Clin North Am, 34(1): 113-129.
9. Kalichman SC, Rompa D (2003). HIV treatment adherence and unprotected sex practices in people receiving antiretroviral therapy. Sex Transm Infect, 79(1): 59-61.
10. Weiser S, Wolfe W, Bangsberg D, et al (2003). Barriers to antiretroviral adherence for patients living with HIV infection and AIDS in Botswana. J Acquir Immune Defic Syndr, 34(3): 281-288.
IssueVol 50 No 8 (2021) QRcode
SectionOriginal Article(s)
DOI https://doi.org/10.18502/ijph.v50i8.6804
HIV-1 Prevalence Drug resistant mutation sites China

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
How to Cite
Zhang Z, Su J, Shen X, Pei B, Zhu F, Ji H, Shi T, Yan Y. Evaluation of the Outcome of Antiviral Therapy among Individ-uals Infected HIV-1 in Suqian District of Jiangsu Province, China. Iran J Public Health. 2021;50(8):1586-1594.